UK drugs company AstraZeneca has rejected an improved final takeover offer from US drugs giant Pfizer Pfizer had made a new offer of  per share valuing AstraZeneca at about bn  the new proposal undervalues the company and its attractive prospects Pfizers pursuit has been under scrutiny because of fears it would hamper AstraZenecas drug research and cut jobs  Pfizer planned to create the worlds largest drug company with its headquarters in New York but based in the UK for tax purposes  In a strategy known as tax inversion Pfizer could pay the UK corporate tax rate of  rather than the  rate applied in the US if it bought AstraZeneca That plan proved controversial with unions and politicians as AstraZeneca employs  people in the UK AstraZeneca chairman Leif Johansson said Pfizers pursuit had been fundamentally driven by the corporate financial benefits Pfizer has failed to make a compelling strategic business or value case he added Of the two companies research and development workforce Pfizer had said it would retain at least  in the UK for at least five years It had also pledged to base its European HQ in Britain AstraZenecas shares fell by more than  after its rejection of the offer  The BBCs business editor Kamal Ahmed said the deal appeared to be over unless AstraZenecas shareholders take an astonishingly aggressive stance and force the board to the negotiating table In its new offer statement Pfizer chief executive Ian Read said We stand by our unprecedented commitments to the UK government  that its improved offer of  per share was final and would not be increased AstraZeneca shareholders were being offered  in cash and  shares in the new firm  worth a combined   for each share currently they hold Pfizer had also promised not to mount a hostile takeover  a direct approach to shareholders of AstraZeneca without the involvement of its board Mr Johansson said that he had made clear to Pfizer that his board could only recommend a bid that was at least  above an offer of  made by Pfizer on Friday  He told Radio s Today programme that AstraZeneca had rejected Pfizers offer for three reasons  that it could create better value for shareholders independently that a takeover would limit its ability to get drugs to market quickly and that the deal carried a big execution risk Its obviously a controversial deal he added  Will Hedden a trader at spread betting firm IG said With Pfizer saying they wont go hostile it looks like it is pretty much dead However some shareholders said they were frustrated by AstraZenecas decision to reject the offer A fund manager at a firm that is among the top ten investors in AstraZeneca told Reuters he was extremely disappointed We do not think the Astra management have done a good job on behalf of shareholders he added A second shareholder within the  largest investors in AstraZeneca said I think large numbers of shareholders out there will be disappointed Edison Investment Research analyst Mick Cooper said AstraZeneca was banking on getting better returns for shareholders by remaining independent than the cash and share combination that Pfizer has offered  AstraZeneca will have six months to demonstrate that it was right to reject Pfizers offer or face the prospect of a fresh approach he said 